Objective: To investigate the relationship between neuromyelitis optica spectrum disorder (NMOSD) and autoantibodies. Methods: Blood samples of 108 NMOSD patients and 38 controls were collected from January 2012 to August 2014. Immunological parameters, including anti-aquaporin 4, antinuclear, anti-ribonucleoprotein, anti-SM, anti-SSA/Ro, anti-SSB/La and anti-ribosomal P-protein autoantibodies were examined. Results: The NMOSD group exhibited a significantly higher percentage of anti-aquaporin 4 antibodies compared with the control group (76.9 vs. 0.0%, p = 0). The positive rates for antinuclear and anti-SSA antibodies in the NMOSD group were also higher than in the control group (35.2 vs. 11.8%, p = 0.001; 13.0 vs. 0.0%, p = 0.044). In total, 36.1% of the patients in the NMOSD group were seropositive for autoantibodies but only 8.3% were diagnosed with definite systemic autoimmune disorders. Conclusions: NMOSD is closely associated with elevated autoantibodies, particularly antinuclear and anti-SSA/Ro antibodies. NMOSD rarely coexists with organ-specific autoimmune diseases.

Keywords:
Autoantibody, Neuromyelitis optica spectrum disorders, Anti-aquaporin 4 antibody
1.
Zekeridou A, Lennon VA: Aquaporin-4 autoimmunity. Neurol Neuroimmunol Neuroinflamm 2015;2:e110.
2.
Metz I, Beissbarth T, Ellenberger D, et al: Serum peptide reactivities may distinguish neuromyelitis optica subgroups and multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 2016;3:e204.
3.
Jarius S, Wildemann B, Paul F: Neuromyelitis optica: clinical features, immunopathogenesis and treatment. Clin Exp Immunol 2014;176:149-164.
4.
Melamed E, Levy M, Waters PJ, et al: Update on biomarkers in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm 2015;2:e134.
5.
Wrzos C, Winkler A, Metz I, et al: Early loss of oligodendrocytes in human and experimental neuromyelitis optica lesions. Acta Neuropathol 2014;127:523-538.
6.
Lucchinetti CF, Mandler RN, McGavern D, et al: A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 2002;125:1450-1461.
7.
Bennett JL, O'Connor KC, Bar-Or A, et al: B lymphocytes in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm 2015;2:e104.
8.
Jarius S, Jacobi C, de Seze J, et al: Frequency and syndrome specificity of antibodies to aquaporin-4 in neurological patients with rheumatic disorders. Mult Scler 2011;17:1067-1073.
9.
Jarius S, Paul F, Franciotta D, et al: Neuromyelitis optica spectrum disorders in patients with myasthenia gravis: ten new aquaporin-4 antibody positive cases and a review of the literature. Mult Scler 2012;18:1135-1143.
10.
Sergio P, Mariana B, Alberto O, Claudia U, Oscar R, Pablo M, Alberto A: Association of neuromyelitis optic (NMO) with autoimmune disorders: report of two cases and review of the literature. Clin Rheumatol 2010;29:1335-1338.
11.
Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG: Revised diagnostic criteria for neuromyelitis optica. Neurology 2006;66:1485-1489.
12.
Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG: The spectrum of neuromyelitis optica. Lancet Neurol 2007;6:805-815.
13.
Hochberg MC: Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
14.
Tan EM, Cohen AS, Fries JF, et al: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-1277.
15.
Vitali C, Bombardieri S, Jonsson R, et al: Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554-558.
16.
Aletaha D, Neogi T, Silman AJ, et al: 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010;62:2569-2581.
17.
Kasukawa R, Tojo T, Miyawaki S: Preliminary Diagnostic Criteria for Classification of Mixed Connective Tissue Disease. Amsterdam, Elsevier, 1987, pp 4-7.
18.
Jarius S, Paul F, Franciotta D, et al: Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures. J Neurol Sci 2011;306:82-90.
19.
Kim HJ, Paul F, Lana-Peixoto MA, Tenembaum S, Asgari N, Palace J: MRI characteristics of neuromyelitis optica spectrum disorder: an international update. Neurology 2015;84;1165-1173.
20.
Pittock SJ, Weinshenker BG, Lucchinetti CF, Wingerchuk DM, Corboy JR, Lennon VA: Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol 2006;67:964-968.
21.
Solomon AJ, Hills W, Chen Z, Rosenbaum J, Bourdette D, Whitham R: Autoantibodies and Sjogren's Syndrome in multiple sclerosis, a reappraisal. PloS One 2013;8:e65385.
22.
Jarius S, Paul F, Ruprecht K, Wildemann B: Low vitamin B12 levels and gastric parietal cell antibodies in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders. J Neurol 2012;259:2743-2745.
23.
Sekaric J, Zivanovic Z, Lucic-Prokin A, et al: Recurrent longitudinally extensive transversal myelitis in a patient with Sjogren's syndrome. Vojnosanit Pregl 2013;70:1056-1058.
24.
Wingerchuk DM, Weinshenker BG: The emerging relationship between neuromyelitis optica and systemic rheumatologic autoimmune disease. Mult Scler 2012;18:5-10.
25.
Zamvil SS, Slavin AJ: Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder? Neurol Neuroimmunol Neuroinflamm 2015;2:e62.
26.
Kim SM, Woodhall MR, Kim JS, Kim SJ, Park KS, et al: Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS. Neurol Neuroimmunol Neuroinflamm 2015;2:e163.
27.
Reindl M, Rostasy K: MOG antibody-associated diseases. Neurol Neuroimmunol Neuroinflamm 2015;2:e60.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.